ACADIA Pharmaceuticals Investor Relations Material

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on improving the lives of patients with serious central nervous system disorders. The Company has a clinical program to assess the safety, efficacy and pharmacokinetic profile of pimavanserin (RE-021), an investigational drug that acts as a selective serotonin 5-hydroxytryptamine 2A receptor inverse agonist (SSRI) to study the central serotonergic system pharmacology and physiology in healthy volunteers and patients with Parkinson's disease psychosis (PDP).